Related Experiment Videos
Biomarker amplification by serum carrier protein binding.
Arpita I Mehta1, Sally Ross, Mark S Lowenthal
1Howard Hughes Medical Institute, Bethesda, MD 20814, USA. arpita.mehta@tufts.edu
Disease Markers
|February 6, 2004
Summary
Most low molecular mass (LMM) biomarkers in serum are bound to carrier proteins like albumin. Analyzing these protein-bound biomarkers, not just free ones, offers new diagnostic insights for diseases like ovarian cancer.
Area of Science:
- Biochemistry
- Proteomics
- Biomarker Discovery
Background:
- The low molecular mass (LMM) range of the serum/plasma proteome is crucial for biomarker discovery.
- Understanding the state of LMM biomarkers (free vs. bound) is essential for accurate detection.
Purpose of the Study:
- To investigate the proportion of LMM biomarkers bound to circulating carrier proteins.
- To determine if carrier protein binding influences biomarker detectability and diagnostic potential.
Main Methods:
- Mass spectroscopic analysis of human serum after molecular mass fractionation.
- Utilized albumin capture techniques to isolate and analyze bound LMM species.
- Investigated specific SELDI-TOF ionic species correlating with ovarian cancer.
Main Results:
- The majority of LMM biomarkers are found bound to carrier proteins.
- Albumin-bound LMM biomarker patterns are distinct from non-albumin-bound patterns.
- Albumin capture amplified a specific LMM biomarker (m/z 6631.7043) associated with ovarian cancer.
Conclusions:
- Carrier protein binding significantly amplifies measurable LMM biomarker concentrations.
- Carrier protein clearance rates, not unbound biomarker rates, largely dictate total serum concentrations.
- Focusing on carrier protein-bound LMM species provides critical diagnostic information, shifting biomarker detection strategies.